Skip to content

Determining Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction

A Pilot Study to Determine the Genetic Biomarkers Predictive of the Development of Prescription Opioid Addiction in Patients Treated for Pain Using a Comparative Transcriptomic Analysis of Gene Expression in Peripheral Blood Cells

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01562353
Enrollment
30
Registered
2012-03-23
Start date
2012-04-30
Completion date
2013-12-31
Last updated
2013-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Usage of Prescription Opioids

Keywords

Opioid Dependence, Opioids for the treatment of pain

Brief summary

This is a clinical study on patients who have been prescribed opioids (narcotic pain relievers) for the treatment of pain, to determine what genetic factors influence outcome of treatment. Procedures include: an initial telephone prescreening, completion of a number of questionnaires, and a blood draw to determine genetic factors. Participants will take part in a one-time clinic visit, during which all procedures will be completed. The investigators hypothesize that several classes of genes, including genes in opioid, pain, and reward pathways, will differentiate opioid-dependent subjects from opioid-exposed nondependent subjects.

Interventions

None listed

Sponsors

Analgesic Solutions
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject is 18 years or older. * Subject is willing and able to speak, read, and write in English and comply with all study procedures. * Subject is willing and able to voluntarily sign and date an Informed Consent Form (ICF), approved by an Institutional Review Board (IRB), prior to the conduct of any study-specific procedures. * Subject has been prescribed opioids for the treatment of pain for at least 6 months at the time of the study. Cases: * Subject has a diagnosis of current prescription opioid dependence (confirmed by the MINI). * Subject had no history of dependence on alcohol or illicit or prescription drugs, including opioids, prior to prescription opioid exposure for the treatment of chronic pain. Patients who have abused these substances but have not met criteria for dependence (confirmed by the MINI and/or medical history) will be included. Controls: * Subject's prescribing physician has reported absence of significant problematic behavior with respect to prescription opioids or other substances while under the physician's care. * Subject has a negative urine drug screen for alcohol, illicit drugs, and nonprescribed controlled substances at screening. * Subject has no current or past substance abuse or dependence (confirmed by the MINI and medical history).

Exclusion criteria

* Subject has any condition that poses undo study-related risk, or that interferes with assessment. * Subject is not willing to have blood drawn or has any condition that in the investigators' opinion precludes having blood drawn.

Design outcomes

Primary

MeasureTime frameDescription
mRNA Levels1 daymRNA levels for all known genes and exons

Secondary

MeasureTime frameDescription
TEQ1 dayTrauma Exposure Questionnare
LSQ1 dayLife Stress Questionnaire
POCS1 dayPrescription Opioid Craving Scale
FTQ1 dayFamily Tree Questionnaire
mARCI1 dayModified Addiction Research Center Inventory
MINI1 dayMini International Neuropsychiatric Interview
POAQ1 dayPrescription Opioid Analgesic Questionnaire

Countries

United States

Contacts

Primary ContactKcennia Sacramed, BSc
ksacramed@analgesicsolutions.com781-444-9605
Backup ContactStephen L Wright, MD
swright@analgesicsolutions.com781-444-9605

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026